Edding Genor Group FY2025 cash and cash equivalents jumps 844.29% to RMB 1.1 billion; revenue falls 2.3% to RMB 2.5 billion

Reuters03-27

Edding Genor Group FY2025 cash and cash equivalents jumps 844.29% to RMB 1.1 billion; revenue falls 2.3% to RMB 2.5 billion

Edding Genor published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB2.5 billion, down 2.3%.
Net profit was RMB399.3 million, up 2.9%.
Adjusted net profit was RMB470.6 million and adjusted EBITDA was RMB950.4 million.
Cash and cash equivalents rose to RMB1.1 billion, while interest-bearing bank and other borrowings fell to RMB1.1 billion, following completion of a strategic merger on Dec. 30, 2025.
Research and development expenses increased 33.4% to RMB162.6 million, driven by higher new drug development and testing costs as GB268 and EDP167 advanced in clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12074485), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622684820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622684820","market":"us","top_or_hot":-1,"title":"Edding Genor Group FY2025 cash and cash equivalents jumps 844.29% to RMB 1.1 billion; revenue falls 2.3% to RMB 2.5 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Edding Genor Group FY2025 cash and cash equivalents jumps 844.29% to RMB 1.1 billion; revenue falls 2.3% to RMB 2.5 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Edding Genor published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB2.5 billion, down 2.3%.\n        </li>\n<li>\n          Net profit was RMB399.3 million, up 2.9%.\n        </li>\n<li>\n          Adjusted net profit was RMB470.6 million and adjusted EBITDA was RMB950.4 million.\n        </li>\n<li>\n          Cash and cash equivalents rose to RMB1.1 billion, while interest-bearing bank and other borrowings fell to RMB1.1 billion, following completion of a strategic merger on Dec. 30, 2025.\n        </li>\n<li>\n          Research and development expenses increased 33.4% to RMB162.6 million, driven by higher new drug development and testing costs as GB268 and EDP167 advanced in clinical development.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12074485), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edding Genor Group FY2025 cash and cash equivalents jumps 844.29% to RMB 1.1 billion; revenue falls 2.3% to RMB 2.5 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdding Genor Group FY2025 cash and cash equivalents jumps 844.29% to RMB 1.1 billion; revenue falls 2.3% to RMB 2.5 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Edding Genor Group FY2025 cash and cash equivalents jumps 844.29% to RMB 1.1 billion; revenue falls 2.3% to RMB 2.5 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Edding Genor published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB2.5 billion, down 2.3%.\n        </li>\n<li>\n          Net profit was RMB399.3 million, up 2.9%.\n        </li>\n<li>\n          Adjusted net profit was RMB470.6 million and adjusted EBITDA was RMB950.4 million.\n        </li>\n<li>\n          Cash and cash equivalents rose to RMB1.1 billion, while interest-bearing bank and other borrowings fell to RMB1.1 billion, following completion of a strategic merger on Dec. 30, 2025.\n        </li>\n<li>\n          Research and development expenses increased 33.4% to RMB162.6 million, driven by higher new drug development and testing costs as GB268 and EDP167 advanced in clinical development.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12074485), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL1Gzm3y:1","article_id":"2622684820","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622684820","pubTimestamp":1774620855,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Edding Genor published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB2.5 billion, down 2.3%.Adjusted net profit was RMB470.6 million and adjusted EBITDA was RMB950.4 million.Cash and cash equivalents rose to RMB1.1 billion, while interest-bearing bank and other borrowings fell to RMB1.1 billion, following completion of a strategic merger on Dec. 30, 2025.Research and development expenses increased 33.4% to RMB162.6 million, driven by higher new drug development and testing costs as GB268 and EDP167 advanced in clinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1583":"高瓴概念","BK1574":"生物医药B类股","06998":"亿腾嘉和"},"translate_title":"Edding Genor Group 2025财年现金及现金等价物跃升844.29%至11亿元人民币；收入下降2.3%至人民币25亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06998":0.9},"content_text":"Edding Genor Group FY2025 cash and cash equivalents jumps 844.29% to RMB 1.1 billion; revenue falls 2.3% to RMB 2.5 billion\n    \n\n\n          Edding Genor published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB2.5 billion, down 2.3%.\n        \n\n          Net profit was RMB399.3 million, up 2.9%.\n        \n\n          Adjusted net profit was RMB470.6 million and adjusted EBITDA was RMB950.4 million.\n        \n\n          Cash and cash equivalents rose to RMB1.1 billion, while interest-bearing bank and other borrowings fell to RMB1.1 billion, following completion of a strategic merger on Dec. 30, 2025.\n        \n\n          Research and development expenses increased 33.4% to RMB162.6 million, driven by higher new drug development and testing costs as GB268 and EDP167 advanced in clinical development.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12074485), on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622684820","isCrawlerRequest":true}